AndreaBozzo/ceres-open-data-index huggingface dataset:
The genetic structure of recombinant inbred mice: high-resolution consensus maps for complex trait analysis

Background
          Recombinant inbred (RI) strains of mice are an important resource used to map and analyze complex traits. They have proved particularly effective in multidisciplinary genetic studies. Widespread use of RI strains has been hampered by their modest numbers and by the difficulty of combining results derived from different RI sets.
        
        
          Results
          We have increased the density of typed microsatellite markers two- to five-fold in each of several major RI sets that share C57BL/6 as a parental strain (AXB, BXA, BXD, BXH and CXB). A common set of 490 markers was genotyped in just over 100 RI strains. Genotypes of around 1,100 additional microsatellites in one or more RI sets were generated, collected and checked for errors. Consensus RI maps that integrate genotypes of approximately 1,600 microsatellite loci were assembled. The genomes of individual strains typically incorporate 45-55 recombination breakpoints. The collected RI set - termed the BXN set - contains approximately 5,000 breakpoints. The distribution of recombinations approximates a Poisson distribution and distances between breakpoints average about 0.5 centimorgans (cM). Locations of most breakpoints have been defined with a precision of < 2 cM. Genotypes deviate from Hardy-Weinberg equilibrium in only a small number of intervals.
        
        
          Conclusions
          Consensus maps derived from RI strains conform almost exactly to theoretical expectation and are close to the length predicted by the Haldane-Waddington equation (x3.6 for a 2-3 cM interval between markers). Non-syntenic associations between different chromosomes introduce predictable distortions in quantitative trait locus (QTL) datasets that can be partly corrected using two-locus correlation matrices.
Compound 528187: 1,3-Cyclopentadiene, 5-pentyl

Chemical compound data from PubChem database. IUPAC Name: 5-pentylcyclopenta-1,3-diene. Molecular Formula: C10H16. Molecular Weight: 136.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
U.S. State and Territorial Gathering Bans: March 11, 2020-August 15, 2021 by County by Day

State and territorial executive orders, administrative orders, resolutions, proclamations, and other official publicly available government communications are collected from government websites and cataloged and coded using Microsoft Excel by one or more coders with one or more additional coders conducting quality assurance.

Data were collected to determine when individuals in states and territories were subject to executive orders, administrative orders, resolutions, proclamations, and other official publicly available government communications related to  COVID-19 banning gatherings of various sizes either (1) generally, or specified that the gathering limit applied only when social distancing was not possible, or (2) even if participants practiced social distancing.

These data are derived from on the publicly available state and territorial executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly ban gatherings found by the CDC, COVID-19 Community Intervention and Critical Populations Task Force, Monitoring and Evaluation Team & CDC, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program from March 11, 2020 through August 15, 2021. These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded, as well as official government communications such as announcements that counties have progressed through new phases of reopening pursuant to an executive order, directive, or other executive branch action, and posted to government websites; news media reports on restrictions were excluded. Recommendations and guidance documents not included or adopted by reference in an order are not included in these data. These data do not include mandatory business closures, curfews, or requirements/recommendations for people to stay in their homes. Due to limitations of the National Environmental Public Health Tracking Network Data Explorer, these data do not include tribes or cities, nor was a distinction made between county orders that applied county-wide versus those that were limited to unincorporated areas of the county. Effective and expiration dates were coded using only the date provided; no distinction was made based on the specific time of the day the order became effective or expired. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.
NNDSS - TABLE 1Q. Hepatitis B, perinatal infection to Hepatitis C, acute, Probable

NNDSS - TABLE 1Q. Hepatitis B, perinatal infection to Hepatitis C, acute, Probable - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ For acute Hepatitis C, only confirmed cases were verified.
Hospital Cost Report Audited Data Print Image: 2011

This print image version of the Institutional Cost Report (ICR) has been audited by the DOH. is the Institutional Cost Report (ICR) is a uniform report completed by New York hospitals to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/hospital/index.htm.
NNDSS - TABLE 1S. Invasive pneumococcal disease, all ages, Confirmed to Invasive pneumococcal disease, all ages, Probable

NNDSS - TABLE 1S. Invasive pneumococcal disease, all ages, Confirmed to Invasive pneumococcal disease, all ages, Probable - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:

U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease.
Weekly Cumulative Doses (in Millions) of Influenza Vaccines Distributed by Season, United States

• Weekly Cumulative Doses (in Millions) of Influenza Vaccines Distributed by Season in the United States. 

• Archived data are available here: https://data.cdc.gov/resource/e5zk-7tx5

• Influenza vaccine is produced by private manufacturers. Additional information is available at https://www.cdc.gov/flu/prevent/vaccine-supply-distribution.htm. These data are submitted to CDC by current U.S.─ licensed manufacturers of influenza vaccine and a subset of influenza vaccine wholesalers and distributors that receive vaccine directly from these manufacturers. These data are not projected but approximate all influenza vaccines distributed in the United States.

• Additional information is available: https://www.cdc.gov/flu/prevent/vaccine-supply-distribution.htm.
Deer Tick Surveillance: Nymphs (May to Sept) excluding Powassan virus: Beginning 2008

This dataset provides the results from collecting and testing nymph deer ticks, also known as blacklegged ticks, or by their scientific name <i>Ixodes scapularis</i>. Collection and testing take place across New York State (excluding New York City) from May to September, when nymph deer ticks are most commonly seen. 

Nymph deer ticks are individually tested for different bacteria and parasites, which includes the bacteria responsible for Lyme disease. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. 

These data only provide nymph tick infections at a precise location and at one point in time. Both measures, tick population density and percentage, of ticks infected with the specified bacteria or parasite can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county.

Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.
Debate: What constitutes 'terminality' and how does it relate to a Living Will?

A moribund and debilitated patient arrives in an emergency department and is placed on life support systems. Subsequently it is determined that she has a 'living will' proscribing aggressive measures should her condition be judged 'terminal' by her physicians. But, as our round table of authorities reveal, the concept of 'terminal' means different things to different people. The patient's surrogates are unable to agree on whether she would desire continuation of mechanical ventilation if there was a real chance of improvement or if she would want to have her living will enforced as soon it's terms were revealed. The problem of the potential ambiguity of a living will is explored.
Patent AT-E399776-T1: [Translated] PYRROLE-2,5-DITHIONE DERIVATIVES AS MODULATORS OF THE LIVER-X RECEPTOR

Chemical patent from PubChem database. Patent Number: AT-E399776-T1. Title: Method for Synthesizing Organic Compounds. Filing Date: 2011-06-15. Inventors: Wilson, James, Brown, Patricia, Lee, David. Abstract: A method for synthesizing organic compounds is disclosed, comprising reacting starting materials under specific conditions to yield the desired produc... IPC Classifications: C08G, C08K, A61K. This patent covers 29 claims related to 2 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
San Francisco – SF Div: Drug-Related Emergency Department Visits, 2004-2011 - Nonmedical Use of Pharmaceuticals

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving the nonmedical use of pharmaceuticals (prescription and over-the-counter medications and dietary supplements) for the San Francisco division of the San Francisco metropolitan area, covering 2004-2011.  Nonmedical use includes patients who took a higher than prescribed or recommended dose of their own medication, patients who took a pharmaceutical prescribed for another person, malicious poisoning of the patient by another individual, and documented substance abuse involving pharmaceuticals
Twenty-nine day study of stability for six different parenteral nutrition mixtures

Background:
          The aim of the study was to assess the particle size stability of six parenteral nutrition regimens, fitted to various pathologies, and used by the University Hospital of Limoges. The mixtures contained glucose (30 or 50%), amino acids (Hyperamine®25), and either long-chain triglycerides (20% Intralipide®) or a combination of medium and long-chain triglycerides (20% Médialipide®). The regimens were not supplemented.
        
        
          Results:
          The visual examinations, particle size analysis and physico-chemical tests, carried out during a long storage period, did not reveal any significant evolution of the lipid emulsions. All the tested formulae were stable for 28 days at 4°C plus 24 h at room temperature.
        
        
          Conclusions:
          It was concluded that the choice of lipid emulsions depends, for these formulae, on the metabolic and clinical needs of the treated patients.
Compound 526540: Relronecine (7R)

Chemical compound data from PubChem database. IUPAC Name: 7-(hydroxymethyl)-2,3,5,8-tetrahydro-1H-pyrrolizin-2-ol. Molecular Formula: C8H13NO2. Molecular Weight: 155.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort

Backgroud
          Bone mineral density (BMD) is a marker of long-term estrogen exposure. BMD measurement has been used in this context to investigate the association of estrogen with breast cancer risk in three cohorts. In order to assess further BMD as a predictor of estrogen related cancer risk, the association of BMD with colorectal and corpus uteri cancer was investigated in the NHANES I Epidemiologic Followup Study (NHEFS) cohort along with breast cancer and prostate cancer.
        
        
          Methods
          Participants were members of the NHEFS cohort who had BMD measurement in 1974–1975. Age, race, and BMI adjusted rate ratios and 95% confidence intervals were calculated for incidence of cancers of the corpus uterus, breast, colorectum, prostate, and of osteoporosis and hip fracture related to baseline BMD.
        
        
          Results
          Data were available for 6046 individuals. One hundred cases of breast cancer, 94 prostate cancers, 115 colorectal cancers, 29 uterine cancers, 110 cases of hip fracture and 103 cases of osteoporosis were reported between 1974 and 1993. Hip fracture and osteoporosis were both significantly inversely associated with BMD. Uterine cancer was positively associated (p = 0.005, test for linear trend) and colorectal cancer negatively associated (p = 0.03) with BMD. No association was found between elevated BMD and incidence of breast cancer (p = 0.74) or prostate cancer (p = 0.37) in the overall cohort, although a weak association was seen between BMD and subsequent breast cancer incidence when BMD was measured in post-menopausal women (p = 0.04).
        
        
          Conclusion
          The findings related to cancers of the uterus and colorectum as well as the weak association of BMD with breast cancer strengthen the use of BMD as a marker of estrogen exposure and cancer risk.
Compound 530680: 4-Ethylbenzoic acid, but-3-yn-2-yl ester

Chemical compound data from PubChem database. IUPAC Name: but-3-yn-2-yl 4-ethylbenzoate. Molecular Formula: C13H14O2. Molecular Weight: 202.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Benefits and Cost Sharing PUF - PY2021

The Benefits and Cost Sharing PUF (BenCS-PUF) is one of the files that make up the Marketplace PUF. The BenCS-PUF contains plan-level data on essential health benefits, coverage limits, and cost sharing for each QHP and SADP. These data either originate from the Plans &amp; Benefits template (i.e., template field), an Excel-based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
Compound 526375: 1,2,7-Tribromo,3-chloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,2,7-tribromo-3-chlorodibenzo-p-dioxin. Molecular Formula: C12H4Br3ClO2. Molecular Weight: 455.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Boston: Drug-Related Emergency Department Visits, 2004-2011 - Nonmedical Use of Pharmaceuticals

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving the nonmedical use of pharmaceuticals (prescription and over-the-counter medications and dietary supplements) for the Boston metropolitan area, covering 2004-2011.  Nonmedical use includes patients who took a higher than prescribed or recommended dose of their own medication, patients who took a pharmaceutical prescribed for another person, malicious poisoning of the patient by another individual, and documented substance abuse involving pharmaceuticals.
Compound 527430: 2-Ethoxy-1,3-dimethoxybenzene

Chemical compound data from PubChem database. IUPAC Name: 2-ethoxy-1,3-dimethoxybenzene. Molecular Formula: C10H14O3. Molecular Weight: 182.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529571: 1,1,3,3-Tetramethyl-2,2,4,4-tetra(n-butyl)cyclotetrasilane

Chemical compound data from PubChem database. IUPAC Name: 1,1,3,3-tetrabutyl-2,2,4,4-tetramethyltetrasiletane. Molecular Formula: C20H48Si4. Molecular Weight: 400.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401080-T1: [Translated] (3-((CHINAZOLINE-4-YL)AMINO)-1H-PYRAZOLE-1- YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER

Quinazoline derivatives of formula (I) for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to processes for their preparation, as well as pharmaceutical compositions containing, them as active ingredient. X is O or NR<SUP>6</SUP>; R<SUP>5 </SUP>is aryl or heteroaryl optionally substituted by 1, 2 or 3 substituents independently selected from halo, hydroxy, cyano, nitro, amino, C<SUB>1-4 </SUB>alkylamino, bis(C<SUB>1-4</SUB>alkyl)amino, C<SUB>1-4</SUB>alkyl, C<SUB>2-4 </SUB>alkenyl, C<SUB>2-4 </SUB>alkynyl, C<SUB>1-4 </SUB>alkoxy, C(O)NHR<SUP>17</SUP>, NHC(0)R<SUP>18 </SUP>and S(O)<SUB>p</SUB>R<SUP>19</SUP>where p is 0,1 or 2; The other substituents area as defined in claim 1.